TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04874428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg Oral Tablet
Description: Administration of one single dose of rivaroxaban (10 mg) in tablet form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg Oral Tablet
Description: Administration of one single dose of apixaban (2.5 mg) in tablet form.
Study: NCT06692075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal life support
Description: ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard ACLS
Description: Standard ACLS in cardioplumonary resuscitation of refractory OHCA
Study: NCT06691334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hifu procedure and PRP injection
Description: Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
Study: NCT06691217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANAKINUMAB (ILARIS®)
Description: Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
Study: NCT06693414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored health promotion education
Description: 14 weeks tailored education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing education
Description: 14 weeks nursing education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing education
Description: 14 weeks nursing education
Study: NCT06693921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided block graft
Description: The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI/guided shell graft
Description: The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
Study: NCT06693544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: Commercially available plant-based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: Commercially available plant-based protein powders
Study: NCT06692400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal tube suctioning
Description: Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
Study: NCT06693778

Intervention type: OTHER
Intervention: electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI
Description: eCDS tool for risk stratification of pediatric mTBI patients
Study: NCT06692582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine
Study: NCT06549777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SE-group
Description: Psychoeducation and information about treatment possibilities + SE-treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Psychoeducation and information about treatment possibilities + Phone
Study: NCT06692582

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrolysed saline rinse
Description: EOS ph = 7, 200 ppm free available Chlorine
Study: NCT06708156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate eye drops 0.01%
Description: Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate eye drops 0.02%
Description: Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops
Description: Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
Study: NCT06708299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CardiolRx
Description: The intervention will be administered orally (via syringe) with food twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CardiolRx
Description: The intervention will be administered orally (via syringe) with food twice daily.
Study: NCT06706336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radon mitigation system
Description: standard radon mitigation system used to reduce radon in homes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: inactive radon mitigation system
Study: NCT06724718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartwatch
Description: Patients in the smartwatch group will undergo rhythm monitoring with a smartwatch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECG
Description: Detected POAF episodes will be confirmed via a 12-lead ECG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG
Description: Detected POAF episodes will be confirmed via a 12-lead ECG
Study: NCT06747260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal breast milk
Description: We administer own-mother's fresh, expressed within 4 hours, breast milk intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart)
Study: NCT06747312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab+SOC
Description: 10mg/kg once a month for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Study: NCT06746168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia
Description: The FTB + iPACK group will receive 12 ml 0,5% ropivacaine for the FTB and 20 ml of ropivacaine 0.5% for the iPACK block under US guidance after spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Ropivacaine
Description: The control group (LIA) will receive 120 ml 0.25% ropivacaine for surgical LIA placement.
Study: NCT06747715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Fat Grafting Fresh followed by Cryopreserved Fat
Description: The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.
Study: NCT06088914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
Study: NCT06055907

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum anti-Xa activity
Description: 4 hours after third dose of dalteparin, serum anti-Xa activity is measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum anti-Xa activity
Description: 4 hours after third dose of dalteparin, serum anti-Xa activity is measured
Study: NCT06746545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+S-1
Description: Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
Study: NCT06747741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNF stretching(Contract relax with agonist contraction)
Description: 1.Passively dorsiflex the patient's foot then ask to perform active planterflexion against resistance and hold for 7-10 sec then ask patient to perform dorsiflexion to the maximum available range.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Static Stretching:(Seated Calf Stretch With a Resistance Band)~1. Sit on the floor with your legs extended.~2. Loop a resistance band around one foot, holding both sides of it with your hands.~3. Gently pull your toes toward your shin until you feel the stretch in your calf.Repeat on the other side.~Isometric Calf Raise:~1. Stand with feet shoulder-width apart and arms at sides.~2. Engage your abs for stability and roll up onto the balls of your feet, lifting both heels off the floor.~3. Hold for 5 seconds, then return to the starting position. Frequency : 5 reps with 5-7Sec hold,3 days per week for 4 weeks (alternatively)
Study: NCT06746233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug (paclitaxel) coated balloon (DCB)
Description: In the experimental arm, a drug-coated balloon (DCB) with a concentration of 3 μg of Paclitaxel per 1 mm² will be used in patients with STEMI following successful lesion preparation (defined as residual stenosis ≤30%, TIMI flow grade 2-3, and absence of flow-limiting dissection). If the result after DCB treatment is unsatisfactory, a bailout drug-eluting stent (DES) will be implanted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second-generation Drug Eluting Stent (DES)
Description: If the patient is randomized to the DES treatment arm, a second-generation drug-eluting stent (DES) will be implanted using standard techniques.
Study: NCT06746181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fraction of inspiration O2(FiO2)
Description: After the patient was admitted to the room, induction of anesthesia was performed after 3 min of preoxygenation. Tracheal intubation was performed after the drugs had taken full effect. Inhaled oxygen concentration was adjusted to each group 10 min after the start of surgery. The first lung recruitment was performed 10 min after oxygen inhalation, and the second lung recruitment was performed when the lung compliance returned to the baseline level.The oxygen concentrations of the four groups were as follows: group A: FiO2 = 30%; group B: FiO2 = 40%; group C: FiO2 = 60%; group D: FiO2 = 80%.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fraction of inspiration O2(FiO2)
Description: After the patient was admitted to the room, induction of anesthesia was performed after 3 min of preoxygenation. Tracheal intubation was performed after the drugs had taken full effect. Inhaled oxygen concentration was adjusted to each group 10 min after the start of surgery. The first lung recruitment was performed 10 min after oxygen inhalation, and the second lung recruitment was performed when the lung compliance returned to the baseline level.The oxygen concentrations of the four groups were as follows: group A: FiO2 = 30%; group B: FiO2 = 40%; group C: FiO2 = 60%; group D: FiO2 = 80%.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fraction of inspiration O2(FiO2)
Description: After the patient was admitted to the room, induction of anesthesia was performed after 3 min of preoxygenation. Tracheal intubation was performed after the drugs had taken full effect. Inhaled oxygen concentration was adjusted to each group 10 min after the start of surgery. The first lung recruitment was performed 10 min after oxygen inhalation, and the second lung recruitment was performed when the lung compliance returned to the baseline level.The oxygen concentrations of the four groups were as follows: group A: FiO2 = 30%; group B: FiO2 = 40%; group C: FiO2 = 60%; group D: FiO2 = 80%.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fraction of inspiration O2(FiO2)
Description: After the patient was admitted to the room, induction of anesthesia was performed after 3 min of preoxygenation. Tracheal intubation was performed after the drugs had taken full effect. Inhaled oxygen concentration was adjusted to each group 10 min after the start of surgery. The first lung recruitment was performed 10 min after oxygen inhalation, and the second lung recruitment was performed when the lung compliance returned to the baseline level.The oxygen concentrations of the four groups were as follows: group A: FiO2 = 30%; group B: FiO2 = 40%; group C: FiO2 = 60%; group D: FiO2 = 80%.
Study: NCT06475599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule + TQB2450 injection
Description: Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response.
Study: NCT06747871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Cigarettes (VLNC)
Description: Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Cigarettes (NNC)
Description: Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.
Study: NCT06747455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG for Therapeutic Use ( BI SAI JI )
Description: After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
Study: NCT06747351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive SC infusion of TAK-881.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants will receive SC infusion of HYQVIA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SC Investigational Needle Sets
Description: The single-use only SC needle set will be used to administer TAK-881/HYQVIA to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
Study: NCT06746662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnobreastfeeding training and consultancy
Description: Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-up
Study: NCT05360329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial geniculate artery embolization
Description: The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
Study: NCT06475599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
Study: NCT06411860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous (SC) injection of placebo.
Study: NCT04937946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
Study: NCT06088914

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
Study: NCT04691544

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema
Study: NCT06411860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Participants will receive a SC injection of olpasiran at dose level 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Participants will receive a SC injection of olpasiran at dose level 1 or 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
Study: NCT04691544

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema
Study: NCT06027996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbable Antibacterial Matrix
Description: Soft tissue support coated with antibiotics
Study: NCT05766891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Participants will receive standard general anesthesia and medications during surgery to control your pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Participants will receive standard general anesthesia and medications during surgery to control your pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Participants will receive standard general anesthesia and medications during surgery to control your pain.
Study: NCT05208814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H single dose
Description: 10 mg TPN171H taken once